Date published: 2026-5-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr390 Inhibitors

Olr390 inhibitors represent a specific class of chemical compounds that interact with the Olr390 protein, a member of the olfactory receptor family. These receptors are G protein-coupled receptors (GPCRs) found primarily in the olfactory epithelium, responsible for detecting odorants and initiating olfactory signal transduction. Olr390, like other olfactory receptors, binds to specific ligands-often volatile organic compounds-triggering a cascade of intracellular events that ultimately result in the perception of smell. Inhibitors of Olr390 can modulate this process by preventing the receptor from binding to its natural ligands or by stabilizing the receptor in a conformation that is less likely to interact with these molecules. This inhibitory action on Olr390 can provide insights into the structural and functional characteristics of olfactory receptors, offering a means to explore the nuances of olfactory signal transduction.

From a chemical perspective, Olr390 inhibitors are typically characterized by their ability to interact with the binding sites of the receptor with high specificity. These inhibitors may be small organic molecules or peptides, each designed to fit precisely within the receptor's binding pocket. The structure-activity relationship (SAR) of these inhibitors is crucial for understanding how alterations in chemical structure can enhance or reduce their affinity for Olr390. The design and synthesis of Olr390 inhibitors often involve extensive computational modeling and biochemical assays to optimize their binding characteristics. By studying these inhibitors, researchers can gain valuable information on the conformational changes in Olr390 upon ligand binding, the nature of the receptor's interaction with various molecules, and the broader implications for GPCR function and olfactory signal processing.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$26.00
$119.00
$213.00
27
(1)

BCR-ABL tyrosine kinase inhibitor, potentially effective against chronic myeloid leukemia.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$63.00
$114.00
$218.00
$349.00
74
(2)

EGFR inhibitor, may block signaling pathways involved in cell proliferation.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

RAF kinase inhibitor, could disrupt cell signaling and tumor growth.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

Src family kinase inhibitor.

Pazopanib

444731-52-6sc-396318
sc-396318A
25 mg
50 mg
$130.00
$182.00
2
(1)

Multi-targeted receptor tyrosine kinase inhibitor, potentially affects cell proliferation and angiogenesis.

XL-184 free base

849217-68-1sc-364657
sc-364657A
5 mg
10 mg
$94.00
$208.00
1
(1)

MET, VEGFR2, and RET inhibitor, could impact tumor growth and metastasis.

Lenvatinib

417716-92-8sc-488530
sc-488530A
sc-488530B
5 mg
25 mg
100 mg
$182.00
$661.00
$1690.00
3
(0)

Multi-targeted tyrosine kinase inhibitor, may affect thyroid cancer progression.

Ribociclib

1211441-98-3sc-507367
10 mg
$450.00
(0)

CDK4/6 inhibitor, potentially halts cell cycle in hormone receptor-positive breast cancer.

BAY 80-6946

1032568-63-0sc-503264
5 mg
$562.00
(0)

PI3K inhibitor, could inhibit signaling pathways in B-cell malignancies.

Ibrutinib

936563-96-1sc-483194
10 mg
$156.00
5
(0)

Bruton's tyrosine kinase inhibitor, designed to affect cell signaling in certain blood cancers.